ALKERMES (8AK MU) stock market data APIs
€23.2494
-0.14(-0.6%)
as of September 17, 2025
Try our APIs with
free plan!
ALKERMES Financial Data Overview
Price chart is built with
Anychart
There is no Profile data available for 8AK.MU.
Prev. Close
23.2494
Open
23.1064
High
23.2494
Low
23.1064
52 wk Range
22.2-35
Market Cap
3 126 M
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get ALKERMES data using free add-ons & libraries
Get ALKERMES Fundamental Data
ALKERMES Fundamental data includes:
- Net Revenue:
- EBITDA:
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: NaN
- EPS/Forecast: NaN
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
ALKERMES News
New
Biotech stocks: Who wins and who loses if RFK, Jr. goes
Investing.com -- RBC Capital said the potential departure of Health and Human Services Secretary Robert F. Kennedy Jr. could have wide-ranging implications for the biotech sector, with both winners an...
Alkermes Appoints Joshua Reed as Chief Financial Officer
DUBLIN, Sept. 12, 2025 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) is pleased to announce the appointment of Joshua Reed as Chief Financial Officer (CFO), effective Monday, Sept. 15, 2025. Mr. Reed wi...
Alkermes Announces Launch of 8th Annual Alkermes Pathways Research Awards® Program
— Competitive Grant Program to Offer Individual Grants of Up to $100,000 per Project — — Areas of Interest Expanded to Include Sleep and Circadian Disturbances Associated With Bipolar I Disorde...
Health Care Roundup: Market Talk
1149 ET – Wall Street appears downbeat on the latest trial results for Alkermes’ narcolepsy treatment alixorexton, though the data came in largely as expected, according to Mizuho analysts. In the...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
